相关实验视频
Updated: Jul 12, 2025

15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
9.6K
在分子病理学,诊断和治疗肌缩性侧面硬化症方面的进展
Hristelina Ilieva1, Mithila Vullaganti2, Justin Kwan3
1Jefferson Weinberg ALS Center, Thomas Jefferson University, Philadelphia, PA, USA.
概括
尽管对肌缩性侧面硬化症 (ALS) 进行了遗传进展,但开发有效的治疗方法进展缓慢. 本综述涵盖了最近的发现和当前的治疗策略,旨在提供个性化的护理,以减缓疾病的进展.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 病理学 病理学 病理学
背景情况:
- 在过去的20年里,肌缩性侧面硬化症 (ALS) 研究取得了重要的遗传和病理学发现.
- 治疗ALS的发展并没有跟上这些科学进步.
研究的目的:
- 审查ALS遗传学和病理学的关键发现.
- 概述疾病特征,诊断,成像和生物标志物的进展.
- 总结目前对ALS护理和治疗的方法.
主要方法:
- 关于ALS研究近期发现的文献综述.
- 分析当前的诊断和治疗策略.
- 综合有关疾病进展因素和异质性的信息.
主要成果:
- 了解ALS遗传学和病理学的进展是相当大的.
- 有效的治疗干预措施仍然有限.
- 目前的护理和治疗方法正在得到完善.
结论:
- 进一步了解ALS进展因素和异质性至关重要.
- 需要一种个性化,多方位的护理方法.
- 其目标是防止疾病的进展,并保持有限残疾患者的尊严.
相关概念视频
Parkinson's Disease: Overview
567
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
567
Alzheimer's Disease: Overview
500
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
500
Alzheimer's Disease: Treatment
200
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
200
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K

